Results 301 to 310 of about 30,600 (344)
Some of the next articles are maybe not open access.
Rivista di neurologia, 1988
The inflammatory myopathies are a heterogeneous group of disorders with recent evidence demonstrating differences in clinical features, pathologic changes, pathogenesis, and response to therapy. The inflammatory myopathies generally produce predominantly proximal, symmetric muscle weakness and wasting. Additional criteria for diagnosis include elevated
Scoppetta C. +4 more
openaire +5 more sources
The inflammatory myopathies are a heterogeneous group of disorders with recent evidence demonstrating differences in clinical features, pathologic changes, pathogenesis, and response to therapy. The inflammatory myopathies generally produce predominantly proximal, symmetric muscle weakness and wasting. Additional criteria for diagnosis include elevated
Scoppetta C. +4 more
openaire +5 more sources
Best Practice & Research Clinical Rheumatology, 1995
New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies.
C V, Oddis, T A, Medsger
openaire +2 more sources
New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies.
C V, Oddis, T A, Medsger
openaire +2 more sources
Current Opinion in Neurology, 1996
As well as myositis caused by infectious agents, there is a spectrum of inflammatory myopathies representing diseases with autoimmune response. Subtypes differing in clinical features and morphological characteristics have been described. This review will emphasize new advances and recent efforts to identify pathogenetic mechanisms and immunological ...
D S, Tews, H H, Goebel
openaire +2 more sources
As well as myositis caused by infectious agents, there is a spectrum of inflammatory myopathies representing diseases with autoimmune response. Subtypes differing in clinical features and morphological characteristics have been described. This review will emphasize new advances and recent efforts to identify pathogenetic mechanisms and immunological ...
D S, Tews, H H, Goebel
openaire +2 more sources
Current Treatment Options in Neurology, 2011
The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM ...
B Jane, Distad +2 more
openaire +2 more sources
The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM ...
B Jane, Distad +2 more
openaire +2 more sources
Continuum, 2022
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.The classification of idiopathic inflammatory myopathies has improved with the integration of myositis ...
openaire +2 more sources
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.The classification of idiopathic inflammatory myopathies has improved with the integration of myositis ...
openaire +2 more sources
Current Treatment Options in Neurology, 1999
Patients with polymyositis or dermatomyositis should be treated with prednisone (approximately 1 mg/kg/d) for an initial period of 4 to 6 weeks. Once improvement occurs, the dose should be tapered and converted to an alternate-day regimen, which should be continued for at least 12 months.
, Mastaglia, , Phillips, , Zilko
openaire +2 more sources
Patients with polymyositis or dermatomyositis should be treated with prednisone (approximately 1 mg/kg/d) for an initial period of 4 to 6 weeks. Once improvement occurs, the dose should be tapered and converted to an alternate-day regimen, which should be continued for at least 12 months.
, Mastaglia, , Phillips, , Zilko
openaire +2 more sources
Veterinary Clinics of North America: Small Animal Practice, 2002
Inflammatory myopathies are the result of infiltration of inflammatory cells into striated muscle, with or without an association with an underlying cause. Two broad classifications are IIMs and secondary inflammatory myopathies associated with other diseases.
openaire +2 more sources
Inflammatory myopathies are the result of infiltration of inflammatory cells into striated muscle, with or without an association with an underlying cause. Two broad classifications are IIMs and secondary inflammatory myopathies associated with other diseases.
openaire +2 more sources
Congenital inflammatory myopathy
Neurology, 1990We present 3 patients with congenital inflammatory myopathy and summarize the literature. CNS involvement (microcephaly/intellectual delay) may or may not be present. Serum creatine kinase activity is elevated, the EMG is myopathic, and the muscle biopsy reveals inflammatory infiltrates, muscle fiber damage, and class I major histocompatibility complex
M, Shevell +4 more
openaire +2 more sources
IDIOPATHIC INFLAMMATORY MYOPATHIES
Neurologic Clinics, 1997Dermatomyositis, polymyositis, and inclusion body myositis are the major categories of idiopathic inflammatory myopathy. These inflammatory myopathies are distinct clinically, histologically, and pathogenically. Features of dermatomyositis and polymyositis can overlap with those of other autoimmune connective tissue diseases.
A A, Amato, R J, Barohn
openaire +2 more sources
Idiopathic Inflammatory Myopathies
Rheumatic Disease Clinics of North America, 1990The idiopathic inflammatory myopathies are a heterogeneous group of uncommon diseases. The incidence rate of IIM is approximately 5 cases per million population, but there appears to be an increase in the rate over the last two decades, particularly in black females.
M E, Cronin, P H, Plotz
openaire +2 more sources